Dynamic Metabolic Response to Adriamycin-Induced Senescence in Breast Cancer Cells
Open accessAbstract
Cellular senescence displays a heterogeneous set of phenotypes linked to tumor suppression; however, after drug treatment, senescence may also be involved in stable or recurrent cancer. Metabolic changes during senescence can provide detailed information on cellular status and may also have implications for the development of effective treatment strategies. The metabolic response to Adriamycin (ADR) treatment, which causes senescence as well as cell death, was obtained with the aid of metabolic profiling and isotope tracing in two human breast cancer cell lines, MCF7 and MDA-MB-231. After 5 days of ADR treatment, more than 60% of remaining, intact cells entered into a senescent state, characterized by enlarged and flattened morphology and positive blue staining using SA-β-gal. Metabolic trajectory analysis showed that the two cell lines’ responses were significantly different and were divided into two distinct stages. The metabolic shift from the first stage to the second was reflected by a partial recovery of the TCA cycle, as well as amino acid and lipid metabolisms. Isotope tracing analysis indicated that the higher level of glutamine metabolism helped maintain senescence. The results suggest that the dynamic changes during senescence indicate a multi-step process involving important metabolic pathways which might allow breast cancer cells to adapt to persistent ADR treatment, while the higher level of anapleurosis may be important for maintaining the senescent state. Ultimately, a better understanding of metabolic changes during senescence might provide targets for cancer therapy and tumor eradication.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The treatment of breast cancer cells with Adriamycin for 5 days induces 60% of cells to become senescent.
“The treatment of breast cancer cells with Adriamycin for 5 days induces 60% of cells to become senescent [61].”
From Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · see citing works
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876 · see citing works
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,469 · see citing works
Nicholson, J. K., & Lindon, J. C. (2008) · Nature · doi:10.1038/4551054a · Cited by 1,889 · see citing works
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708 · see citing works
Sawyers, C. L. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,171 · see citing works
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72931 · Cited by 881 · see citing works
Cellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855 · see citing works
DNA damage checkpoints: from initiation to recovery or adaptation
Bartek, J., & Lukas, J. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.009 · Cited by 784 · see citing works
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Bar‐Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 728 · see citing works
Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705 · see citing works
Metabolomics-based methods for early disease diagnostics
Gowda, G. A. N., Zhang, S., Gu, H., Asiago, V. M., Shanaiah, N., & Raftery, D. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.5.617 · Cited by 690 · see citing works
Self-citationYang, C., Ko, B., Hensley, C. T., Jiang, L., Wasti, A. T., Kim, J., Sudderth, J., Calvaruso, M. A., Lumata, L., Mitsche, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.025 · Cited by 679 · see citing works
Senescent cells as a source of inflammatory factors for tumor progression
Davalos, A. R., Coppe, J.-P., Campisi, J., & Desprez, P.-Y. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9220-9 · Cited by 636 · see citing works
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
Kaplon, J., Zheng, L., Meissl, K., Chaneton, B., Selivanov, V. A., Mackay, G., van der Burg, S. H., Verdegaal, E. M. E., Cascante, M., Shlomi, T., et al. (2013) · Nature · doi:10.1038/nature12154 · Cited by 633 · see citing works
(2003) · PubMed · Cited by 608 · see citing works
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013) · Nature · doi:10.1038/nature12437 · Cited by 541 · see citing works
From Ancient Pathways to Aging Cells—Connecting Metabolism and Cellular Senescence
Wiley, C. D., & Campisi, J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.010 · Cited by 440 · see citing works
Cellular senescence: a link between cancer and age-related degenerative disease?
Campisi, J., Andersen, J. K., Kapahi, P., & Melov, S. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.001 · Cited by 421 · see citing works
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2006) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 411 · see citing works
Dimensionality Reduction and Visualization in Principal Component Analysis
Ivosev, G., Burton, L., & Bonner, R. F. (2008) · Analytical Chemistry · doi:10.1021/ac800110w · Cited by 286 · see citing works
Aird, K. M., Zhang, G., Li, H., Tu, Z., Bitler, B. G., Garipov, A., Wu, H., Wei, Z., Wagner, S. N., Herlyn, M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.004 · Cited by 285 · see citing works
IsoCor: correcting MS data in isotope labeling experiments
Millard, P., Létisse, F., Sokol, S., & Portais, J. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts127 · Cited by 278 · see citing works
Stable isotope-resolved metabolomics and applications for drug development
Fan, T. W. ‐., Lorkiewicz, P. K., Sellers, K., Moseley, H., Higashi, R. M., & Lane, A. N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.007 · Cited by 209 · see citing works
Elmore, L. W., Di, X., Dumur, C., Holt, S. E., & Gewirtz, D. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1462 · Cited by 151 · see citing works
Budczies, J., Denkert, C., Müller, B. M., Brockmöller, S. F., Klauschen, F., Győrffy, B., Dietel, M., Richter-Ehrenstein, C., Marten, U., Salek, R. M., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-334 · Cited by 150 · see citing works
Cellular senescence: hot or what?
Evan, G. I., & di Fagagna, F. D. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.11.009 · Cited by 109 · see citing works
Back, J. H., Rezvani, H. R., Zhu, Y., Guyonnet‐Dupérat, V., Athar, M., Ratner, D., & Kim, A. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240598 · Cited by 86 · see citing works
Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence
McKenna, E., Traganos, F., Zhao, H. L., & Darżynkiewicz, Z. (2012) · Cell Cycle · doi:10.4161/cc.21506 · Cited by 63 · see citing works
Oblong, J. E. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.04.005 · Cited by 61 · see citing works
Lane, A. N., Tan, J. D., Wang, Y., Yan, J., Higashi, R. M., & Fan, T. W. ‐. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.01.010 · Cited by 55 · see citing works
Metabolic changes during cellular senescence investigated by proton NMR-spectroscopy
Gey, C., & Seeger, K. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.02.002 · Cited by 48 · see citing works
Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway
Chou, W., Hu, L., Hsiung, C., & Shen, C. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv079 · Cited by 47 · see citing works
Nakano, M., Nakashima, A., Nagano, T., Ishikawa, S., Kikkawa, U., & Kamada, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080411 · Cited by 47 · see citing works
Klontzas, M. E., Vernardis, S. I., Heliotis, M., Tsiridis, E. E., & Mantalaris, A. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0315 · Cited by 46 · see citing works
Wu, M., Ye, H., Shao, C., Zheng, X., Li, Q., Wang, L., Zhao, M., Lu, G., Chen, B., Zhang, J., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00111 · Cited by 45 · see citing works
Madhu, B., Narita, M., Jauhiainen, A., Menon, S., Stubbs, M., Tavaré, S., Narita, M., & Griffiths, J. R. (2015) · Metabolomics · doi:10.1007/s11306-015-0838-z · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy
Saleh, T., Bloukh, S., Carpenter, V. J., Alwohoush, E., Bakeer, J., Darwish, S., Azab, B., & Gewirtz, D. A. (2020) · Cancers · doi:10.3390/cancers12040822 · Cited by 289 · see citing works
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies
Wyld, L., Bellantuono, I., Tchkonia, T., Morgan, J., Turner, O., Foss, F., George, J., Danson, S., & Kirkland, J. L. (2020) · Cancers · doi:10.3390/cancers12082134 · Cited by 235 · see citing works
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124 · see citing works
Luo, J., Sun, T., Liu, Z., Liu, Y., Liu, J., Wang, S., Shi, X., & Zhou, H. (2025) · International Journal of Oral Science · doi:10.1038/s41368-025-00380-w · Cited by 56 · see citing works
Nishi, K., Yoshii, A., Abell, L., Zhou, B., Frausto, R. F., Ritterhoff, J., McMillen, T. S., Sweet, I. R., Wang, Y., Gao, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112641 · Cited by 46 · see citing works
Saleh, T., Alhesa, A., Al-Balas, M., Abuelaish, O. M., Mansour, A. T., Awad, H., El‐Sadoni, M., Carpenter, V. J., & Azab, B. (2021) · Bioscience Reports · doi:10.1042/bsr20210079 · Cited by 38 · see citing works
Insights into the role of senescence in tumor dormancy: mechanisms and applications
DeLuca, V. J., & Saleh, T. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10082-6 · Cited by 36 · see citing works
Autophagy and senescence in cancer therapy
Patel, N. H., Bloukh, S., Alwohosh, E., Alhesa, A., Saleh, T., & Gewirtz, D. A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.01.002 · Cited by 33 · see citing works
The Expression of the Senescence-Associated Biomarker Lamin B1 in Human Breast Cancer
Saleh, T., Alhesa, A., El‐Sadoni, M., Shahin, N. A., Alsharaiah, E., Shboul, S. A., Awad, H., Bloukh, S., Al-Balas, M., Alsalem, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030609 · Cited by 27 · see citing works
Untargeted Lipidomics Highlight the Depletion of Deoxyceramides during Therapy‐Induced Senescence
Millner, A., Lizardo, D. Y., & Atilla‐Gokcumen, G. E. (2020) · PROTEOMICS · doi:10.1002/pmic.202000013 · Cited by 24 · see citing works
The Dynamic Process and Its Dual Effects on Tumors of Therapy-Induced Senescence
Liao, C., Xiao, Y., & Liu, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s285083 · Cited by 22 · see citing works
Nguyen, Y. T.-K., Moon, J. Y., Ryu, J., Eum, S. M., Bách, T. T., & Cho, S. K. (2019) · Molecules · doi:10.3390/molecules24122273 · Cited by 18 · see citing works
Wang, L., Du, Y., Xu, B., Deng, X., Liu, Q., Zhong, Q.-Q., Chen-xiang, W., Ji, S., Guo, M., & Tang, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00928 · Cited by 15 · see citing works
DNA damage-induced senescence is associated with metabolomic reprogramming in breast cancer cells
George, N., Joshi, M. B., & Satyamoorthy, K. (2023) · Biochimie · doi:10.1016/j.biochi.2023.09.021 · Cited by 14 · see citing works
Abu-Humaidan, A. H. A., Ismail, M. A., Ahmad, F. M., Shboul, S. A., Barham, R., Tadros, J. S., Alhesa, A., El‐Sadoni, M., Alotaibi, M. R., Ababneh, N. A., et al. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12727 · Cited by 13 · see citing works
Senescence-related genes as prognostic indicators in breast cancer survival
Ungvari, Z. I., Ungvari, A., Fekete, M., Kiss, C., & Győrffy, B. (2024) · GeroScience · doi:10.1007/s11357-024-01384-w · Cited by 14 · see citing works
Shao, C., Lu, W., Wan, N., Wu, M., Bao, Q., Tian, Y., Lu, G., Wang, N., Hao, H., & Ye, H. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00138 · Cited by 12 · see citing works
Issitt, T., Sweeney, S. T., Brackenbury, W. J., & Redeker, K. R. (2022) · Metabolites · doi:10.3390/metabo12070599 · Cited by 10 · see citing works
Ritterhoff, J., McMillen, T. S., Foundas, H., Palkovacs, R., Poschet, G., Caudal, A., Liu, Y., Most, P., Walker, M. A., & Tian, R. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00611.2023 · Cited by 9 · see citing works
Yan, Y., Xiang, C., & Zhang, D. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220729103430 · Cited by 5 · see citing works
You, R., Wang, L., Liu, L., Wang, Y., Han, K., Lin, H., Wang, Y., Raftery, D., & Guan, Y. (2021) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3174 · Cited by 4 · see citing works
Self-citationIssitt, T., Sweeney, S. T., Brackenbury, W. J., & Redeker, K. R. (2022) · Preprints.org · doi:10.20944/preprints202205.0069.v1 · Cited by 2 · see citing works
Utami, W., & FARRAS, N. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16s5.52474
Najmina, M., Tanjaya, N. K., Ishii, S., & Uto, K. (2025) · Science and Technology of Advanced Materials Methods · doi:10.1080/27660400.2025.2525061
- Authors
- You, R., Dai, J., Zhang, P., Barding, G. A., & Raftery, D.
- Affiliations
- South China Normal University (CN)
- University of Washington (US)
- Southwest University (CN)
- Corresponding author
- Raftery, Daniel
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2018-12-15
- Volume
- 8
- Issue
- 4
- Pages
- 95
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC6315875
- OpenAlex
- W2905553940
- Cited by
- 24
- References
- 37
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 3
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01GM085291, P30CA015704)
- Topics
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- cellular senescence, doxorubicin, breast cancer, metabolic response, TCA cycle, glutamine metabolism, amino acid metabolism, lipid metabolism, isotope tracing, MCF-7 cells, MDA-MB-231 cells, drug resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
